VTP-201227

VTP-201227 is a small molecule drug developed as a topical agent for the treatment of psoriasis, with potential applications in other dermatological conditions. It acts as a potent and selective inhibitor of cytochrome P450 oxidoreductase (POR), an enzyme involved in electron transfer to cytochrome P450 enzymes in the skin. By inhibiting POR, VTP-201227 modulates local metabolic processes implicated in psoriatic inflammation and promotes natural healing mechanisms within the skin. The compound was designed to be rapidly inactivated upon entering systemic circulation, aiming for an improved safety profile compared to other topical agents. Developed by Vitae Pharmaceuticals, clinical development reached Phase 2 before being discontinued[1][2][3].